July 01, 2010
The FDA has approved Purdue's Butrans (buprenorphine) Transdermal System for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.
July 01, 2010
Sangamo BioSciences announced positive Phase 2 data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy (DN).
June 25, 2010
McNeil Consumer Healthcare announced that it does not anticipate having sources of supply for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility before the end of 2010.
June 22, 2010
The FDA has approved Namenda XR, an extended-release formulation of memantine HCl, for the treatment of moderate to severe dementia of the Alzheimer's type.
June 18, 2010
Victory Pharma announced that it has launched Rybix ODT (tramadol HCl, orally disintegrating tablets) for the management of moderate to moderately severe pain in patients ≥16 years of age.